75 related articles for article (PubMed ID: 2533393)
1. [Immunomodulating basic therapy of rheumatoid arthritis using ciamexone].
Baerwald C; Goebel KM; Krause A; Heymanns J
Schweiz Med Wochenschr; 1989 Dec; 119(49):1769-71. PubMed ID: 2533393
[TBL] [Abstract][Full Text] [Related]
2. A randomized controlled trial of ciamexon versus placebo in the immunomodulatory treatment of rheumatoid arthritis.
Baerwald C; Goebel KM; Krause A; Heymanns J
Arthritis Rheum; 1990 May; 33(5):733-8. PubMed ID: 2189417
[TBL] [Abstract][Full Text] [Related]
3. [The active rosette-formation reaction in assessing the immunomodulating activity of basic preparations in patients with rheumatoid arthritis].
Senchilo IV; Vasil'eva EV
Ter Arkh; 1992; 64(6):77-80. PubMed ID: 1440346
[No Abstract] [Full Text] [Related]
4. [Initial results of the clinical use of the immunostimulant bestatin (3-amino-2-hydroxy-4-phenylbutyryl leucine) in patients with chronic polyarthritis].
Meske S; Vogt P; Maly FE; Seitz M; Müller W
Z Rheumatol; 1985; 44(5):231-6. PubMed ID: 4082790
[TBL] [Abstract][Full Text] [Related]
5. Leflunomide, a novel immunomodulator for the treatment of active rheumatoid arthritis.
Goldenberg MM
Clin Ther; 1999 Nov; 21(11):1837-52; discussion 1821. PubMed ID: 10890256
[TBL] [Abstract][Full Text] [Related]
6. [Combined immunomodulating therapy in rheumatoid arthritis].
Oliunin IuA; Balabanova RM
Ter Arkh; 1996; 68(5):13-6. PubMed ID: 9082588
[TBL] [Abstract][Full Text] [Related]
7. The effects of interferon-beta treatment of synovial inflammation and expression of metalloproteinases in patients with rheumatoid arthritis.
Smeets TJ; Dayer JM; Kraan MC; Versendaal J; Chicheportiche R; Breedveld FC; Tak PP
Arthritis Rheum; 2000 Feb; 43(2):270-4. PubMed ID: 10693865
[TBL] [Abstract][Full Text] [Related]
8. High dose versus low dose fludarabine in the treatment of patients with severe refractory rheumatoid arthritis.
Davis JC; Fessler BJ; Tassiulas IO; McInnes IB; Yarboro CH; Pillemer S; Wilder R; Fleisher TA; Klippel JH; Boumpas DT
J Rheumatol; 1998 Sep; 25(9):1694-704. PubMed ID: 9733448
[TBL] [Abstract][Full Text] [Related]
9. Peripheral blood T lymphocyte subsets in active rheumatoid arthritis--effects of different therapies on previously untreated patients.
Karlsson-Parra A; Svenson K; Hällgren R; Klareskog L; Forsum U
J Rheumatol; 1986 Apr; 13(2):263-8. PubMed ID: 3088273
[TBL] [Abstract][Full Text] [Related]
10. Ciamexone, a highly selective immunomodulator--a tool for autoimmune diseases?
Bicker U; Usadel KH
Klin Wochenschr; 1986 Dec; 64(24):1261-6. PubMed ID: 3493387
[TBL] [Abstract][Full Text] [Related]
11. A pilot study of a long acting somatostatin analogue for the treatment of refractory rheumatoid arthritis.
Paran D; Elkayam O; Mayo A; Paran H; Amit M; Yaron M; Caspi D
Ann Rheum Dis; 2001 Sep; 60(9):888-91. PubMed ID: 11502617
[TBL] [Abstract][Full Text] [Related]
12. Oral pulsed dexamethasone therapy in early rheumatoid arthritis: a pilot study.
Kroot EJ; Huisman AM; Van Zeben J; Wouters JM; Van Paassen HC
Ann N Y Acad Sci; 2006 Jun; 1069():300-6. PubMed ID: 16855157
[TBL] [Abstract][Full Text] [Related]
13. Two-year, blinded, randomized, controlled trial of treatment of active rheumatoid arthritis with leflunomide compared with methotrexate. Utilization of Leflunomide in the Treatment of Rheumatoid Arthritis Trial Investigator Group.
Cohen S; Cannon GW; Schiff M; Weaver A; Fox R; Olsen N; Furst D; Sharp J; Moreland L; Caldwell J; Kaine J; Strand V
Arthritis Rheum; 2001 Sep; 44(9):1984-92. PubMed ID: 11592358
[TBL] [Abstract][Full Text] [Related]
14. Role of new population of peripheral CD11c(+)CD8(+) T cells and CD4(+)CD25(+) regulatory T cells during acute and remission stages in rheumatoid arthritis patients.
Kao JK; Hsue YT; Lin CY
J Microbiol Immunol Infect; 2007 Oct; 40(5):419-27. PubMed ID: 17932602
[TBL] [Abstract][Full Text] [Related]
15. Autoantibodies against Tmu and B lymphocytes in patients with rheumatoid arthritis.
Meijer CJ; Cnossen J; Lafeber GJ; Damsteeg MJ; Cats A
Clin Exp Immunol; 1982 Feb; 47(2):368-80. PubMed ID: 6978781
[TBL] [Abstract][Full Text] [Related]
16. Immunopharmacological evaluation of bucillamine in rheumatoid arthritis.
Matsuno H; Kitano T; Matsushita I; Tsuji H; Ochiai H
Drugs Exp Clin Res; 1993; 19(5):205-11. PubMed ID: 8174492
[TBL] [Abstract][Full Text] [Related]
17. p205 is a major target of autoreactive T cells in rheumatoid arthritis.
Bläss S; Schumann F; Hain NA; Engel JM; Stuhlmüller B; Burmester GR
Arthritis Rheum; 1999 May; 42(5):971-80. PubMed ID: 10323453
[TBL] [Abstract][Full Text] [Related]
18. [Subreum efficacy and tolerance in patients with early rheumatic arthritis].
Stepanets OV; Chichasova NV; Nasonova MB; Nasonov EL
Klin Med (Mosk); 2001; 79(11):58-62. PubMed ID: 11811114
[TBL] [Abstract][Full Text] [Related]
19. A novel predictor of clinical response to methotrexate in patients with rheumatoid arthritis: a pilot study of in vitro T cell cytokine suppression.
Haroon N; Srivastava R; Misra R; Aggarwal A
J Rheumatol; 2008 Jun; 35(6):975-8. PubMed ID: 18464312
[TBL] [Abstract][Full Text] [Related]
20. Effects of inoculation with attenuated autologous T cells in patients with rheumatoid arthritis.
van Laar JM; Miltenburg AM; Verdonk MJ; Leow A; Elferink BG; Daha MR; Cohen IR; de Vries RR; Breedveld FC
J Autoimmun; 1993 Apr; 6(2):159-67. PubMed ID: 8098938
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
